| Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 |
|---|
| Net income (loss) | 117 | -234 | 51 |
|---|
| Depreciation | 64 | 64 | 77 |
|---|
| Amortization of intangible assets | 87 | 82 | 81 |
|---|
| Impairment of investment in unconsolidated affiliate | - | 10 | - |
|---|
| Loss on extinguishment of debt | -21 | - | - |
|---|
| Deferred income taxes | -4 | -74 | 3 |
|---|
| Share-based compensation expense | 14 | 21 | 32 |
|---|
| Accretion expense | 2 | 2 | 2 |
|---|
| Unrealized foreign exchange loss (gain) | -1 | 4 | -6 |
|---|
| Unrealized loss (gain) on derivatives not designated as hedging instruments | - | -3 | 2 |
|---|
| Amortization of debt issuance costs | 6 | 6 | 9 |
|---|
| Other | 13 | 7 | 5 |
|---|
| Accounts receivable | 16 | 13 | 22 |
|---|
| Inventories | 20 | -14 | 10 |
|---|
| Other current assets | 4 | 6 | -4 |
|---|
| Accounts payable | 20 | 1 | -5 |
|---|
| Accrued liabilities | 2 | 21 | 4 |
|---|
| Litigation settlement | - | - | -35 |
|---|
| Illinois EO litigation settlement | - | - | 408 |
|---|
| Georgia EO litigation settlement | - | - | -35 |
|---|
| Income taxes payable / receivable, net | 10 | -12 | 1 |
|---|
| Other liabilities | -0 | 0 | -2 |
|---|
| Other long-term assets | 4 | 5 | 0 |
|---|
| Net cash provided by (used in) operating activities | 282 | 278 | -148 |
|---|
| Net income (loss) | 117 | -234 | 51 |
|---|
| Depreciation | 64 | 64 | 77 |
|---|
| Amortization of intangible assets | 87 | 82 | 81 |
|---|
| Impairment of investment in unconsolidated affiliate | - | 10 | - |
|---|
| Loss on extinguishment of debt | -21 | - | - |
|---|
| Deferred income taxes | -4 | -74 | 3 |
|---|
| Share-based compensation expense | 14 | 21 | 32 |
|---|
| Accretion expense | 2 | 2 | 2 |
|---|
| Unrealized foreign exchange loss (gain) | -1 | 4 | -6 |
|---|
| Unrealized loss (gain) on derivatives not designated as hedging instruments | - | -3 | 2 |
|---|
| Amortization of debt issuance costs | 6 | 6 | 9 |
|---|
| Other | 13 | 7 | 5 |
|---|
| Accounts receivable | 16 | 13 | 22 |
|---|
| Inventories | 20 | -14 | 10 |
|---|
| Other current assets | 4 | 6 | -4 |
|---|
| Accounts payable | 20 | 1 | -5 |
|---|
| Accrued liabilities | 2 | 21 | 4 |
|---|
| Litigation settlement | - | - | -35 |
|---|
| Illinois EO litigation settlement | - | - | 408 |
|---|
| Georgia EO litigation settlement | - | - | -35 |
|---|
| Income taxes payable / receivable, net | 10 | -12 | 1 |
|---|
| Other liabilities | -0 | 0 | -2 |
|---|
| Other long-term assets | 4 | 5 | 0 |
|---|
| Net cash provided by (used in) operating activities | 282 | 278 | -148 |
|---|
| Purchases of property, plant and equipment | 102 | 182 | 215 |
|---|
| Purchase of BioScience Laboratories, LLC, net of cash acquired | 14 | - | - |
|---|
| Purchase of BioScience Laboratories, LLC, net of cash acquired | 14 | - | - |
|---|
| Purchase of mandatorily redeemable noncontrolling interest in Nelson Laboratories Fairfield, Inc. | 12 | - | - |
|---|
| Purchase of mandatorily redeemable noncontrolling interest in Nelson Laboratories Fairfield, Inc. | 12 | - | - |
|---|
| Purchase of Regulatory Compliance Associates Inc., net of cash acquired | 31 | -0 | - |
|---|
| Purchase of Regulatory Compliance Associates Inc., net of cash acquired | 31 | -0 | - |
|---|
| Other investing activities | 1 | -0 | -0 |
|---|
| Other investing activities | 1 | -0 | -0 |
|---|
| Net cash used in investing activities | -160 | -182 | -215 |
|---|
| Net cash used in investing activities | -160 | -182 | -215 |
|---|
| Proceeds from Issuance of Long-Term Debt | - | 200 | 500 |
|---|
| Payment of revolving credit facility | - | - | 200 |
|---|
| Purchase of noncontrolling interests in China subsidiaries | 8 | - | - |
|---|
| Purchase of noncontrolling interests in China subsidiaries | 8 | - | - |
|---|
| Payments of debt issuance costs and prepayment premium | 7 | 0 | 26 |
|---|
| Payments of debt issuance costs and prepayment premium | 7 | 0 | 26 |
|---|
| Payments of long-term borrowings | 100 | - | 3 |
|---|
| Payments of long-term borrowings | 100 | - | 3 |
|---|
| Shares withheld for employee taxes on equity awards | 1 | 0 | 4 |
|---|
| Shares withheld for employee taxes on equity awards | 1 | 0 | 4 |
|---|
| Other financing activities | -1 | -2 | -2 |
|---|
| Other financing activities | -1 | -2 | -2 |
|---|
| Net cash provided by (used in) financing activities | -117 | 198 | 266 |
|---|
| Net cash provided by (used in) financing activities | -117 | 198 | 266 |
|---|
| Effect of exchange rate changes on cash and cash equivalents | 0 | -4 | 2 |
|---|
| Net increase (decrease) in cash and cash equivalents, including restricted cash | 4 | 289 | -95 |
|---|
| Cash paid during the period for interest | 59 | 76 | 174 |
|---|
| Income Taxes Paid, Net | 52 | 75 | 50 |
|---|
| Capital Expenditures Incurred but Not yet Paid | 15 | 16 | 17 |
|---|
| Purchases of property, plant and equipment | 102 | 182 | 215 |
|---|
| Purchase of BioScience Laboratories, LLC, net of cash acquired | 14 | - | - |
|---|
| Purchase of BioScience Laboratories, LLC, net of cash acquired | 14 | - | - |
|---|
| Purchase of mandatorily redeemable noncontrolling interest in Nelson Laboratories Fairfield, Inc. | 12 | - | - |
|---|
| Purchase of mandatorily redeemable noncontrolling interest in Nelson Laboratories Fairfield, Inc. | 12 | - | - |
|---|
| Purchase of Regulatory Compliance Associates Inc., net of cash acquired | 31 | -0 | - |
|---|
| Purchase of Regulatory Compliance Associates Inc., net of cash acquired | 31 | -0 | - |
|---|
| Other investing activities | 1 | -0 | -0 |
|---|
| Other investing activities | 1 | -0 | -0 |
|---|
| Net cash used in investing activities | -160 | -182 | -215 |
|---|
| Net cash used in investing activities | -160 | -182 | -215 |
|---|
| Proceeds from Issuance of Long-Term Debt | - | 200 | 500 |
|---|
| Payment of revolving credit facility | - | - | 200 |
|---|
| Purchase of noncontrolling interests in China subsidiaries | 8 | - | - |
|---|
| Purchase of noncontrolling interests in China subsidiaries | 8 | - | - |
|---|
| Payments of debt issuance costs and prepayment premium | 7 | 0 | 26 |
|---|
| Payments of debt issuance costs and prepayment premium | 7 | 0 | 26 |
|---|
| Payments of long-term borrowings | 100 | - | 3 |
|---|
| Payments of long-term borrowings | 100 | - | 3 |
|---|
| Shares withheld for employee taxes on equity awards | 1 | 0 | 4 |
|---|
| Shares withheld for employee taxes on equity awards | 1 | 0 | 4 |
|---|
| Other financing activities | -1 | -2 | -2 |
|---|
| Other financing activities | -1 | -2 | -2 |
|---|
| Net cash provided by (used in) financing activities | -117 | 198 | 266 |
|---|
| Net cash provided by (used in) financing activities | -117 | 198 | 266 |
|---|
| Effect of exchange rate changes on cash and cash equivalents | 0 | -4 | 2 |
|---|
| Net increase (decrease) in cash and cash equivalents, including restricted cash | 4 | 289 | -95 |
|---|
| Cash paid during the period for interest | 59 | 76 | 174 |
|---|
| Income Taxes Paid, Net | 52 | 75 | 50 |
|---|
| Capital Expenditures Incurred but Not yet Paid | 15 | 16 | 17 |
|---|